Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Gefitinib”

347 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 347 results

Not applicableStudy completedNCT01448187
What this trial is testing

Descriptive Pharmacoepidemiological Study of Patients Treated With Iressa

Who this might be right for
Lung Cancer
AstraZeneca 361
Not applicableUnknownNCT02738684
What this trial is testing

Predict Gefitinib' s Efficacy for Lung Cancer by Plasma Free Nucleic Acids EGFR Gene Mutation Test

Who this might be right for
Lung Adenocarcinoma
Southwest Hospital, China 100
Large-scale testing (Phase 3)Study completedNCT00357734
What this trial is testing

Iressa Follow-up Trial

Who this might be right for
Lung CancerBreast Cancer
AstraZeneca 14
Testing effectiveness (Phase 2)Study completedNCT00298688
What this trial is testing

IRESSA in Relapsed and Refractory Small Cell Lung Cancer

Who this might be right for
Small Cell Lung Cancer
AstraZeneca 56
Testing effectiveness (Phase 2)Study completedNCT01580735
What this trial is testing

ARQ 197 Plus Erlotinib in Patient With Locally Advanced or Metastatic EGFR Mutation-positive Non-small-cell Lung Cancer

Who this might be right for
Non-small-cell Lung Cancer
Kyowa Kirin Co., Ltd. 40
Not applicableStudy completedNCT00252759
What this trial is testing

Iressa Case Control Study in Japan

Who this might be right for
Non-small Cell Lung Cancer
AstraZeneca 6,000
Testing effectiveness (Phase 2)Study completedNCT00238797
What this trial is testing

A Phase II Exploratory, Multicentre, Open-label, Non-comparative Study of ZD1839 (Iressa) and Radiotherapy in the Treatment of Patients With Glioblastoma Multiforme

Who this might be right for
Glioblastoma
AstraZeneca 36
Early research (Phase 1)Study completedNCT00502060
What this trial is testing

Phase I Study of AZD2171 co-Administered With Fixed Multiple Oral Doses of ZD1839 in Patients With Advanced Cancer

Who this might be right for
Advanced Tumor
AstraZeneca 65
Testing effectiveness (Phase 2)Study completedNCT00014170
What this trial is testing

Gefitinib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

Who this might be right for
Adult Giant Cell GlioblastomaAdult GlioblastomaAdult Gliosarcoma
National Cancer Institute (NCI) 92
Testing effectiveness (Phase 2)Study completedNCT01039948
What this trial is testing

A Phase 1b/2 Study in Asian Subjects With Non-Small Cell Lung Cancer

Who this might be right for
Carcinoma, Non-Small Cell-LungLung NeoplasmsLung Cancer+1 more
AVEO Pharmaceuticals, Inc. 203
Testing effectiveness (Phase 2)Study completedNCT01485809
What this trial is testing

Efficacy and Safety Study of Gefitinib in Squamous NSCLC Patients Who Failed First-Line Chemotherapy

Who this might be right for
Squamous Cell Carcinoma of Bronchus
Seoul Veterans Hospital 36
Testing effectiveness (Phase 2)Study completedNCT00052169
What this trial is testing

Therapy With Docetaxel and ZD1839 for Patients Who Have Advanced Breast Cancer

Who this might be right for
Breast Neoplasms
NSABP Foundation Inc 33
Testing effectiveness (Phase 2)Study completedNCT00317772
What this trial is testing

Topotecan and Gefitinib (Iressa) for Ovarian, Peritoneal, or Fallopian Tube Cancer

Who this might be right for
Ovarian CancerPeritoneal NeoplasmsFallopian Tube Cancer
M.D. Anderson Cancer Center 19
Testing effectiveness (Phase 2)UnknownNCT01965275
What this trial is testing

High-Dose,Pulsatile Erlotinib/Gefitinib for Advanced NSCLC Patients After Failure of Standard Dose EGFR-TKIs

Who this might be right for
Self EfficacyDrug Toxicity
Anhui Medical University 20
Testing effectiveness (Phase 2)Study completedNCT01167244
What this trial is testing

Trial of BMS-690514 in Non-Small Cell Lung Cancer Subjects Who Have Been Treated With Gefitinib or Erlotinib and Are Genotypically EGFR Mutation Positive or Who Have Had a Prior Response

Who this might be right for
Non-Small-Cell Lung Carcinoma
Bristol-Myers Squibb 11
Testing effectiveness (Phase 2)WithdrawnNCT02347839
What this trial is testing

NEoadjuvant Gefitinib fOllowed by Surgery and gefiTinib In unresectAble sTage III NSCLC With EGFR Mutations.

Who this might be right for
Lung Cancer
Sun Yat-sen University
Testing effectiveness (Phase 2)Study completedNCT01256437
What this trial is testing

Evaluating Preventive Therapy With Oint Threolone, Synthomycine or Aqua Cream, for EGFR'I Induced Acneiform Rash

Who this might be right for
Acneiform Rash
Rabin Medical Center 90
Large-scale testing (Phase 3)Study completedNCT01404260
What this trial is testing

Intercalating and Maintenance Use of Iressa Versus Chemotherapy in Selected Advanced Non Small Cell Lung Cancer

Who this might be right for
Non-small Cell Lung Cancer
Guangdong Association of Clinical Trials 219
Early research (Phase 1)Study completedNCT00127829
What this trial is testing

Study Evaluating Gefitinib (IRESSA®) in Subjects With Solid Malignancies That Are Locally Advanced, Recurrent or Metastatic

Who this might be right for
Tumors
AstraZeneca 66
Large-scale testing (Phase 3)WithdrawnNCT00090675
What this trial is testing

Maintenance ZD1839 (IRESSA®) Following Completion of Front Line, Platinum-Based, Double Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer

Who this might be right for
Non-Small-Cell Lung Carcinoma
AstraZeneca
Load More Results